Browse the evidence

Glutamine serves as a major energy substrate for immune cells and is required for lymphocyte proliferation and glutathione synthesis.

Your immune cells rely on glutamine for energy. While your body makes some, severe stress or illness can deplete it. Ensuring adequate protein intake supports this natural production.

Muscle atrophy is driven by the hyperactivation of the ubiquitin-proteasome and autophagy-lysosome pathways, regulated by transcription factors like FoxO and NF-kB, leading to the upregulation of 'atrogenes' such as MuRF1 and MAFbx.

Muscle loss is driven by specific degradation pathways (proteasome, autophagy) regulated by transcription factors (FoxO, NF-kB). Preventing atrophy involves modulating these pathways, not just 'eating more'.

Hypertension prevalence and mortality burden are significantly higher in low- and middle-income countries compared to high-income countries, with deaths attributable to high blood pressure increasing in Asia and sub-Saharan Africa.

Recognize that hypertension is a major killer in low- and middle-income countries. Support global health initiatives that scale up treatment coverage and improve community effectiveness in these regions.

The enzyme PTP1B acts as a critical negative regulator of insulin signaling; its absence or inhibition enhances insulin sensitivity and protects against high-fat-diet-induced obesity and insulin resistance.

PTP1B is an enzyme that turns off insulin signals. Inhibiting it improves insulin sensitivity in animal models without obvious negative side effects, making it a promising target for future diabetes treatments.

Ectopic lipid accumulation (specifically diacylglycerol) in skeletal muscle and liver directly causes insulin resistance by activating specific protein kinase C (PKC) isoforms (PKCθ in muscle, PKCε in liver), which impair insulin receptor signaling.

Insulin resistance in obesity is driven by specific fat molecules (DAG) accumulating in muscle and liver, which block insulin signals. Reducing ectopic fat (via weight loss or exercise) can restore sensitivity.

Hepatic insulin resistance is characterized by a 'selective' defect where insulin fails to suppress gluconeogenesis but continues to stimulate de novo lipogenesis, driven by substrate flux (fatty acids and glucose) rather than insulin signaling alone.

In T2D, the liver ignores insulin's command to stop making glucose, but still responds to high sugar/fat intake by making more fat. Managing carbohydrate and fat intake is critical to reducing liver fat and glucose production.

Adipose tissue inflammation and macrophage infiltration cause insulin resistance by increasing lipolysis, which floods the liver with fatty acids and glycerol, driving gluconeogenesis and hyperglycemia independently of hepatic insulin signaling.

In obesity, inflamed fat tissue releases excess fatty acids and glycerol, which force the liver to produce more glucose and fat. Reducing adipose inflammation and lipolysis (via weight loss) improves liver function.

The FTO obesity-risk allele (rs1421085) promotes obesity by disrupting ARID5B binding, which derepresses IRX3/IRX5 expression in adipocyte progenitors, shifting them from energy-dissipating beige adipocytes to energy-storing white adipocytes and reducing mitochondrial thermogenesis.

This research identifies a specific genetic variant (FTO rs1421085) that causes fat cells to store more energy and burn less as heat. While you cannot change your DNA, this finding highlights a biological target (IRX3/IRX5) for future therapies. For now, standard energy balance principles apply, but this mechanism explains why some individuals may have a biological predisposition to store fat more efficiently.

Knocking down IRX3 or IRX5 in adipocytes from individuals with the FTO risk allele restores mitochondrial thermogenesis by a factor of 7, effectively reversing the obesity-associated phenotype.

This finding suggests that future drugs targeting IRX3 or IRX5 could help people with the FTO obesity gene burn more fat. It is not a current lifestyle intervention but a promising area for pharmaceutical development.

The endogenous circadian pacemaker significantly modulates sleep propensity, with sleep latency being shortest (highest propensity) when sleep coincides with the minimum of the core body temperature rhythm, and longest (lowest propensity) when it coincides with the maximum.

To fall asleep faster, try to align your bedtime with your body's natural temperature minimum, which typically occurs in the early morning hours (e.g., 4-6 AM) for most people. If you must sleep at other times, expect longer sleep latency. Consistent sleep-wake times help stabilize this rhythm.

The circadian pacemaker significantly modulates the amount of REM sleep, with maximum REM sleep occurring shortly after the minimum of the core body temperature rhythm, and minimum REM sleep occurring during the plateau phase.

If you are concerned about REM sleep deprivation, note that REM sleep is naturally higher in the early morning hours (shortly after the body temperature minimum). Disrupting this phase (e.g., by waking up too early) may disproportionately reduce REM sleep.

Slow-wave activity (SWA, 0.75-4.5 Hz) in non-REM sleep is modulated by both the circadian pacemaker and the homeostatic sleep process, with the circadian modulation peaking around the minimum of the core body temperature rhythm.

Deep sleep (SWA) is highest when you sleep during your biological night (temperature minimum). Additionally, SWA increases with the duration of prior wakefulness. To maximize deep sleep, ensure you are sleep-deprived enough (homeostatic pressure) and sleeping during your circadian night.

Chronic low-grade inflammation (inflammaging) is a fundamental endogenous driver of aging, creating a vicious cycle with cellular senescence that leads to organ dysfunction and age-related diseases.

Aging is closely linked to chronic, low-grade inflammation. While this paper is a mechanistic review, the implication is that strategies reducing systemic inflammation may support healthy aging. Focus on lifestyle factors known to modulate inflammation, such as regular physical activity, adequate sleep, and a nutrient-dense diet, as these are foundational to managing 'inflammaging'.

Immunosenescence, characterized by a decline in immune cell function and an increase in pro-inflammatory cytokine secretion, impairs the clearance of senescent cells and pathogens, exacerbating aging.

Immune function declines with age, leading to increased susceptibility to infection and chronic inflammation. Maintaining immune health through vaccination, stress management, and nutrient adequacy is crucial for older adults.

For deaths related to mental/behavioral disorders, neurological conditions, and non-transport accidents, lower BMI (up to 24-27 kg/m²) is associated with increased mortality risk, showing an inverse linear association rather than a J-shape.

Don't assume being thin is always safer. For neurological and mental health-related causes of death, this study found that lower BMI (down to 24-27) was associated with higher risk. Maintaining a healthy weight (not underweight) is important for protecting against these specific outcomes.

Adipose tissue inflammation, driven by immune cell infiltration (macrophages, T cells) and pro-inflammatory cytokines (TNFα, IL-6), is a causal factor for systemic insulin resistance in obesity.

Obesity is not just about storing energy; it triggers inflammation in fat tissue that blocks insulin action. Reducing this inflammation, potentially through weight loss or anti-inflammatory strategies, can improve insulin sensitivity.

Gastrointestinal satiation signals, specifically cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY), regulate meal termination and size through neural and hormonal pathways to the hindbrain, acting synergistically with gastric distention.

Your body uses specific gut hormones (CCK, GLP-1, PYY) to tell your brain when to stop eating. These are released in response to nutrients, especially fats and proteins, in the intestine. While these signals are crucial for normal eating, simply relying on stomach stretching (volume) is less effective than consuming nutrient-dense foods that trigger these hormonal pathways.

Grip strength follows a life-course trajectory of increasing to a peak in early adulthood (males 29-39 years, females 26-42 years), maintaining through midlife, and declining thereafter, with significant gender differences emerging from adolescence.

Use grip strength as a vital sign that changes with age. Do not compare your current strength to your 20-year-old self or to the opposite sex. Instead, compare your measurement to age- and gender-specific centiles. A value below the 10th centile for your age/gender group may indicate 'weak grip' and warrants further clinical assessment for frailty or sarcopenia risk, especially if you are over 50.

Embryonic skeletal muscle formation is primarily driven by extrinsic morphogen gradients (Wnt, Shh, BMP) that pattern the somite and regulate intrinsic transcription factors (Pax3, MyoD, Myf5), whereas adult muscle regeneration relies on the activation of quiescent satellite cells that reuse this same genetic hierarchy.

Understanding muscle biology requires recognizing that muscle growth and repair are governed by complex genetic and signaling pathways. While resistance training stimulates these pathways, the underlying biological machinery for creating and maintaining muscle tissue is deeply rooted in developmental processes that remain active in adults via satellite cells.

Satellite cells are the essential progenitor cells for adult skeletal muscle regeneration, residing in a quiescent state within the niche until activated by injury or other stimuli to differentiate into new muscle fibers.

For long-term muscle health and repair, the activation of satellite cells is crucial. While resistance training is the primary stimulus, the biological reality is that these cells must be activated to contribute to muscle growth and repair.

Metformin treatment in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) reduces hepatic glucose output primarily by inhibiting gluconeogenesis, leading to improved glycemic control and preferential loss of adipose tissue.

If you have type 2 diabetes and are overweight, metformin can help lower your blood sugar and reduce body fat without causing muscle loss. Start with a low dose to minimize stomach upset, and gradually increase it as tolerated. It works by reducing the amount of sugar your liver produces.

Metformin and thiazolidinediones improve glucose homeostasis in Type 2 Diabetes patients partly by activating AMPK.

Metformin is a common medication for Type 2 Diabetes that works, in part, by activating AMPK. This helps your body manage blood sugar and insulin sensitivity more effectively.

Adipose tissue functions as an active endocrine organ that secretes adipocytokines (e.g., TNF-α, IL-6, leptin, adiponectin) which regulate whole-body metabolism, insulin sensitivity, and inflammation, rather than serving merely as inert fat storage.

Understand that your fat tissue is an active organ that sends signals to your brain and other organs. It doesn't just store energy; it regulates your appetite, insulin sensitivity, and inflammation through hormones like leptin and adiponectin. Managing fat mass is therefore managing a complex hormonal system, not just caloric storage.

Obesity induces a state of chronic low-grade inflammation in adipose tissue, primarily driven by macrophage infiltration and the secretion of pro-inflammatory cytokines (TNF-α, IL-6), which directly impairs insulin signaling and contributes to insulin resistance.

Excess body fat, particularly visceral fat, triggers an inflammatory response involving immune cells (macrophages) that release hormones like TNF-α and IL-6. These hormones interfere with insulin signaling, leading to insulin resistance. Reducing visceral fat can help lower this inflammation and improve metabolic health.